What Is Retatrutide?
The triple-receptor agonist explained — mechanism and lab handling.
Home › Compound guides › Tirzepatide
The "dual agonist" — a single peptide that targets two metabolic receptors. Here's what it is, how it works, and how it's handled in the lab.
Tirzepatide sits right in the middle of the GLP-1 family. It's newer and more complex than semaglutide, but a step simpler than retatrutide — and that "dual" design is exactly what makes it one of the most studied research peptides today.
Tirzepatide is a synthetic peptide built as a dual agonist: one molecule that activates two receptors — the GLP-1 and the GIP receptor. Both belong to the body's incretin system, which helps regulate glucose and appetite signalling. It's supplied to researchers as a lyophilized powder.
An agonist switches a receptor on. Tirzepatide engages two at once:
Hitting both is the idea behind a "dual" agonist — engaging two complementary pathways with a single compound, which is why tirzepatide is studied as a step beyond single-receptor peptides like semaglutide.
Single, dual, triple — semaglutide hits one receptor, tirzepatide two, retatrutide three.
| Compound | Type | Receptors |
|---|---|---|
| Semaglutide | Single agonist | GLP-1 |
| Tirzepatide | Dual agonist | GLP-1 + GIP |
| Retatrutide | Triple agonist | GLP-1 + GIP + glucagon |
More receptors isn't automatically "better" — each compound has its own research profile and is studied for different reasons.
Always confirm what's actually in the vial. A reputable source includes a Certificate of Analysis (COA) with third-party HPLC purity and mass-spec identity for that batch — here's how to read one.
We recommend Vital Chems for tested compounds and bacteriostatic water.